Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit
Identifieur interne : 002263 ( Main/Merge ); précédent : 002262; suivant : 002264Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit
Auteurs : A. Wozniacka [Pologne] ; A. Carter [États-Unis] ; D P MccauliffeSource :
- Lupus [ 0961-2033 ] ; 2002-02.
English descriptors
- Teeft :
- Acad dermatol, Acta, Acta dermatol venereol, Ammation, Ammatory, Antigen presentation, Antimalarial, Antimalarial drugs, Antimalarial treatment, Apoptosis, Arch dermatol, Arthritis, Arthritis rheum, Autoimmune, Awozniacka, Bene, Bene cial effects, Biochem, Biochem pharmac, Chloroquine, Chloroquine phosphate, Chloroquine treatment, Cial, Clin, Clin pharmac, Cutaneous, Cutaneous lupus awozniacka, Cutaneous lupus erythematosus, Cutaneous manifestations, Cytokine, Dermatol, Erythema, Erythematosus, Glucose, Healthy volunteers, Human skin, Hydroxychloroquine, Hydroxychloroquine sulfate, Immune system, Immunol, Keratinocytes, Lipid, Lipid peroxidation, Lupus, Lupus erythematosus, Lymphocyte, Lysosomal, Lysosomal enzymes, Lysosome, Macrophage, Major histocompatibility, Pathogenic mechanisms, Peroxidation, Pharmac, Phospholipase, Proc natl acad, Promoter polymorphism, Prostaglandin, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatol, Subacute, Subacute cutaneous lupus erythematosus, Systemic, Systemic lupus erythematosus, Therapeutic bene, Therapeutic effects, Tumor necrosis factor, Venereol.
Abstract
Antimalarials are arguably the best modality currently available for treating patients with cutaneous lupus erythematosus (LE). Although antimalarials have been used for decades in treating cutaneous LE, the precise mechanisms by which they provide therapeutic benefit are not well defined. The putative mechanisms by which antimalarials might provide therapeutic benefit to patients with cutaneous LE include a number of interrelated anti-inflammatory and immunosuppressive effects that include photoprotection, lysosomal stabilization, suppression of antigen presentation, and inhibition of prostaglandin and cytokine synthesis. If we had a more precise understanding of how antimalarials provide therapeutic benefit in cutaneous LE we might gain better insight into the pathogenic mechanisms of LE and ways of developing better therapies for afflicted patients.
Url:
DOI: 10.1191/0961203302lu147rr
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000003
- to stream Istex, to step Curation: 000003
- to stream Istex, to step Checkpoint: 001068
Links to Exploration step
ISTEX:D1B8B9FED400F9EAF5C836E9B3771CC97CF47529Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit</title><author wicri:is="90%"><name sortKey="Wozniacka, A" sort="Wozniacka, A" uniqKey="Wozniacka A" first="A" last="Wozniacka">A. Wozniacka</name></author><author wicri:is="90%"><name sortKey="Carter, A" sort="Carter, A" uniqKey="Carter A" first="A" last="Carter">A. Carter</name></author><author wicri:is="90%"><name sortKey="Mccauliffe, D P" sort="Mccauliffe, D P" uniqKey="Mccauliffe D" first="D P" last="Mccauliffe">D P Mccauliffe</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D1B8B9FED400F9EAF5C836E9B3771CC97CF47529</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1191/0961203302lu147rr</idno><idno type="url">https://api.istex.fr/ark:/67375/M70-D3KSCF86-M/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000003</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000003</idno><idno type="wicri:Area/Istex/Curation">000003</idno><idno type="wicri:Area/Istex/Checkpoint">001068</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001068</idno><idno type="wicri:doubleKey">0961-2033:2002:Wozniacka A:antimalarials:in:cutaneous</idno><idno type="wicri:Area/Main/Merge">002263</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit</title><author wicri:is="90%"><name sortKey="Wozniacka, A" sort="Wozniacka, A" uniqKey="Wozniacka A" first="A" last="Wozniacka">A. Wozniacka</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Dermatology, Medical University of Lodz, Lodz, Krzemieniecka</wicri:regionArea><wicri:noRegion>Krzemieniecka</wicri:noRegion></affiliation></author><author wicri:is="90%"><name sortKey="Carter, A" sort="Carter, A" uniqKey="Carter A" first="A" last="Carter">A. Carter</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Medical School, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region><settlement type="city">Chapel Hill (Caroline du Nord)</settlement></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation></author><author wicri:is="90%"><name sortKey="Mccauliffe, D P" sort="Mccauliffe, D P" uniqKey="Mccauliffe D" first="D P" last="Mccauliffe">D P Mccauliffe</name><affiliation></affiliation><affiliation><wicri:noCountry code="no comma">E-mail: dpmccauliffe@juno.com</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Lupus</title><idno type="ISSN">0961-2033</idno><idno type="eISSN">1477-0962</idno><imprint><publisher>Sage Publications</publisher><pubPlace>Sage CA: Thousand Oaks, CA</pubPlace><date type="published" when="2002-02">2002-02</date><biblScope unit="volume">11</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="71">71</biblScope><biblScope unit="page" to="81">81</biblScope></imprint><idno type="ISSN">0961-2033</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0961-2033</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad dermatol</term><term>Acta</term><term>Acta dermatol venereol</term><term>Ammation</term><term>Ammatory</term><term>Antigen presentation</term><term>Antimalarial</term><term>Antimalarial drugs</term><term>Antimalarial treatment</term><term>Apoptosis</term><term>Arch dermatol</term><term>Arthritis</term><term>Arthritis rheum</term><term>Autoimmune</term><term>Awozniacka</term><term>Bene</term><term>Bene cial effects</term><term>Biochem</term><term>Biochem pharmac</term><term>Chloroquine</term><term>Chloroquine phosphate</term><term>Chloroquine treatment</term><term>Cial</term><term>Clin</term><term>Clin pharmac</term><term>Cutaneous</term><term>Cutaneous lupus awozniacka</term><term>Cutaneous lupus erythematosus</term><term>Cutaneous manifestations</term><term>Cytokine</term><term>Dermatol</term><term>Erythema</term><term>Erythematosus</term><term>Glucose</term><term>Healthy volunteers</term><term>Human skin</term><term>Hydroxychloroquine</term><term>Hydroxychloroquine sulfate</term><term>Immune system</term><term>Immunol</term><term>Keratinocytes</term><term>Lipid</term><term>Lipid peroxidation</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lymphocyte</term><term>Lysosomal</term><term>Lysosomal enzymes</term><term>Lysosome</term><term>Macrophage</term><term>Major histocompatibility</term><term>Pathogenic mechanisms</term><term>Peroxidation</term><term>Pharmac</term><term>Phospholipase</term><term>Proc natl acad</term><term>Promoter polymorphism</term><term>Prostaglandin</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatol</term><term>Subacute</term><term>Subacute cutaneous lupus erythematosus</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Therapeutic bene</term><term>Therapeutic effects</term><term>Tumor necrosis factor</term><term>Venereol</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Antimalarials are arguably the best modality currently available for treating patients with cutaneous lupus erythematosus (LE). Although antimalarials have been used for decades in treating cutaneous LE, the precise mechanisms by which they provide therapeutic benefit are not well defined. The putative mechanisms by which antimalarials might provide therapeutic benefit to patients with cutaneous LE include a number of interrelated anti-inflammatory and immunosuppressive effects that include photoprotection, lysosomal stabilization, suppression of antigen presentation, and inhibition of prostaglandin and cytokine synthesis. If we had a more precise understanding of how antimalarials provide therapeutic benefit in cutaneous LE we might gain better insight into the pathogenic mechanisms of LE and ways of developing better therapies for afflicted patients.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002263 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002263 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:D1B8B9FED400F9EAF5C836E9B3771CC97CF47529
|texte= Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit
}}
| This area was generated with Dilib version V0.6.33. |  |